Evercore ISI analyst Cory Kasimov raised the firm’s price target on Vir Biotechnology (VIR) to $18 from $12 and keeps an Outperform rating on the shares. The Astellas (ALPMY) deal is a “BIG win” for the bispecific pipeline that underpins the “promising” mCRPC data update, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology price target raised to $17 from $13 at BofA
- Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley
- Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
- Vir Biotechnology, Astellas Forge Major Prostate Cancer Alliance
- Vir Biotechnology reports Q4 EPS (31c), consensus (50c)